Physician Assistant Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

James Cook

Neurological Surgery Idaho Falls, ID Physician Assistant

NPI 1497838478 CMS profile 1117918

1975 Martha Ave, Ste A, Idaho Falls, ID 83404

Open in the dashboard

General payments

$2,980

33 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Cook of Idaho Falls, ID is reported in the CMS Open Payments database as having received $2,980 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,000 9
2024 General $423 6
2023 General $166 5
2022 General $97 4
2021 General $278 8
2020 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Cook
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to James Cook were reported at $2,000. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year James Cook Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $16 $294 $76–$2,174 $114
2021 $278 $387 $105–$2,432 $132
2022 $97 $542 $139–$2,989 $149
2023 $166 $534 $145–$2,697 $160
2024 $423 $574 $155–$3,046 $164
2025 $2,000 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medical Device Business Services, Inc. $1,792 6 payments
  2. Medtronic, Inc. $262 6 payments
  3. Relievant Medsystems, Inc. $131 3 payments
  4. Active Medical, LLC $114 1 payment
  5. Nalu Medical, Inc. $102 2 payments
  6. DePuy Synthes Sales Inc. $94 1 payment
  7. Centinel Spine, LLC $85 1 payment
  8. Kuros Biosciences USA, Inc $63 1 payment
  9. Zimvie Inc. $54 1 payment
  10. Stryker Corporation $51 1 payment
  11. Other $232 10 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $1,628 2 payments
  2. Food and Beverage $1,352 31 payments
Products named General payments · program years 2020–2025
  1. Velys $1,792 6 payments
  2. MAZOR X SYSTEM $148 3 payments
  3. Intracept Pain $131 3 payments
  4. Intracept Pain $131 3 payments
  5. Nalu Neurostimulation System $102 2 payments
  6. Teligen $94 1 payment
  7. PRODISC L $85 1 payment
  8. MAGNETOS $63 1 payment
  9. Mobi-C $54 1 payment
  10. INFINITY ADAPTIS $51 1 payment
  11. Other $399 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

281

Median for Physician Assistant: 241

Drug cost

$6,144

Median for Physician Assistant: $4,110

Branded share of claims

45.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 40 $3,017
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 66 $895
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 29 $772
Ondansetron Odt Ondansetron Brand 11 $455
Oxycodone Hcl Generic 31 $288
Nabumetone Generic 13 $242
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 21 $230
Cyclobenzaprine Hcl Generic 23 $82
Tramadol Hcl Generic 23 $77
Gabapentin Generic 12 $77

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$18,423

Medicare's payments for the services billed

Medicare patients

102

Average age 74

Services billed

292

45 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Depression 23%
Ischemic heart disease 21%
Atrial fibrillation 20%
Chronic kidney disease 13%
COPD 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record